Literature DB >> 17073912

Atrial fibrillation following subconjunctival injection of mydricaine number 02.

Ranasiri D Keembiyage, Grant L Raymond, Henry S Newland.   

Abstract

Mydricaine is a mydriatic agent used as a subconjunctival injection to maintain perioperative mydriasis. The drug consists of a mixture of 1.3 mg atropine sulphate, 0.12 mg adrenaline and 8.4 mg procaine hydrochloride in a single vial of 0.4 mL. It is common practice to use mydricaine injections during vitreoretinal surgery in the Royal Adelaide Hospital. Even though the drug is used widely in many vitreoretinal centres, mydricaine is not listed in the British National Formulary nor Monthly Index of Medical Specialities. Therefore, case reports provide the main forum for reporting side-effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073912     DOI: 10.1111/j.1442-9071.2006.01331.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  1 in total

1.  Subconjunctival 0.1% epinephrine versus placebo in maintenance of mydriasis during vitrectomy: a randomized controlled trial.

Authors:  Rafael B de Araújo; Breno M S Azevedo; Thais S Andrade; Maria F Abalem; Mário L R Monteiro; Pedro C Carricondo
Journal:  Int J Retina Vitreous       Date:  2018-10-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.